# Harrow Inc. (HROW) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $38.54, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Harrow Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.20**. A PEG of 0.20 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 5.2×**. Each dollar of revenue is priced at 5.2×.
- **Price / book: 94.9×**. The shares trade at 94.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 0.3%** (5-yr avg 0.5%). Free cash flow equals 0.3% of the market value, below its five-year average of 0.5%, so the shares are pricier on cash than usual.

## Profitability
- **Gross margin: 73.3%**. Harrow Inc. keeps 73.3% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -1.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -1.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -9.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -0.9%**. Return on all capital, debt included, is -0.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -9.3%**. Each dollar of assets produces -9.3% of profit.

## Growth
- **Revenue growth (1 yr): 36.4%** (3-yr 45.4%/yr, 5-yr 41.0%/yr). Revenue grew 36.4% over the last year, against 41.0% a year compounded over five years.
- **EPS growth (1 yr): 71.4%**. Earnings per share rose 71.4%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 4.77**. Debt is 4.77 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Altman Z-score: 3.61**. A Z-score of 3.61 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Harrow Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Harrow Inc.; the consensus is strong_buy, with an average price target of $67.50 (+75% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 6.5%** (YTD -21.3%, 3-mo 16.1%). The shares are up 6.5% over twelve months including dividends.
- **From 52-week high: -29.7%** (35.0% above the low). Trading 30% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 46**. An RSI of 46 is neutral.
- **Beta (1 yr): 1.50** (volatility 65%). Beta of 1.50 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=HROW · Page: https://foliofundamentals.com/stocks/hrow

Not investment advice.